This Space Biotech Just Got $1.1M to Speed Up Drug Discovery

Jan de Vries · 2026-08-11

What if the next big breakthrough in medicine didn't come from a lab on Earth, but from orbit? That's the bet Exobiosphere is making. The Luxembourg-based space BioTech startup just locked in €1 million (roughly $1.1 million) in non-dilutive funding, and it's planning to use that cash to push its ambitious orbital drug discovery platform into the commercial mainstream. The grant comes through Luxembourg's Jeune Entreprise Innovante (JEI) aid scheme and is administered by the Ministry of the Economy. For a young company like Exobiosphere, this kind of support is huge — it's money that doesn't require giving up equity, which means the founders keep full control while they scale. ### Why Space Matters for Drug Discovery You might be wondering: why would anyone run drug experiments in space? It sounds like science fiction, but there's real science behind it. In microgravity, biological processes behave differently. Cellular senescence, immune dysregulation, neuronal development, and even tumor aggressiveness all accelerate in ways they simply don't here on Earth. That acceleration is the key. It lets researchers observe disease mechanisms and drug responses that standard in-vitro models can't capture. In other words, space gives you a faster, more detailed look at how diseases progress — and how drugs might stop them. ### The Tech Behind the Mission Exobiosphere's core product is the Orbital High-Throughput Screening (OHTS) system. It's designed to run more than 2,000 simultaneous automated experiments per mission, with everything mirrored back to Earth-based control systems in real time. That's a massive leap from what's currently possible on the ground. The platform handles the whole workflow autonomously. It feeds and differentiates cells, dispenses toxic compounds or therapeutic drugs, processes samples, and performs plate-reader and microscopy-based readouts. That means it supports everything from complex 3D disease modeling to automated stem cell differentiation and compound potency testing. ### What the Funding Will Do Kyle Acierno, co-founder and CEO of Exobiosphere, is clear about what this grant means for the company. "This grant lands at exactly the right moment and makes a real difference for a company at our stage," he said. "It allows us to expand our commercial activities, strengthen our team, and bring our technological offer to more pharmaceutical and biotech partners around the world." The money will go toward three main areas: - Commercial expansion and international business development - Strengthening internal operations and team capacity - Scaling up the OHTS platform for more missions The company is also exploring several therapeutic areas, including oncology, aging, neurodegeneration, radiation response, inflammation, and cardiovascular disease. That's a broad pipeline, but the platform is designed to be flexible enough to handle it. ### The JEI Scheme Explained The Jeune Entreprise Innovante scheme is specifically designed for young, research-intensive companies with strong growth potential. It pairs non-dilutive public funding with private investment to help firms move into their next phase of growth. Here's how it works: the scheme co-finances up to 70% of a company's estimated financing needs over as long as three years, capped at €1 million (about $1.1 million). But there's a catch — applicants need to hold an innovation certificate from Luxinnovation confirming their status as an innovative enterprise. Exobiosphere received that certificate ahead of the grant, which shows they've already passed a rigorous review process. ### What's Next for Exobiosphere Founded in 2024 by Acierno alongside Dr. Bruno Santos and Dr. Olivia Borgue, Exobiosphere is building what it calls the world's first standardized space-based high-throughput testing platform. The vision is to give pharmaceutical and BioTech companies the ability to run automated experiments in orbit at scale — and, ultimately, to find "cures from space." With this funding secured, the company is well-positioned to bring that vision closer to reality. The team is focused on scaling up operations, building international partnerships, and proving that orbital drug discovery isn't just a concept — it's a commercial service that can change how we develop medicines. For the broader space BioTech sector, this is a positive signal. It shows that investors and governments are willing to back companies that push the boundaries of what's possible. And if Exobiosphere delivers on its promise, we might see a future where the next life-saving drug was first tested hundreds of miles above our heads.